Spruce Biosciences
SPRB
44 hedge funds and large institutions have $74.5M invested in Spruce Biosciences in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 2 closing their positions.
850% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 2
273% more capital invested
Capital invested by funds: $20M → $74.5M (+$54.5M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
57% more funds holding
Funds holding: 28 → 44 (+16)
7.55% more ownership
Funds ownership: 77.38% → 84.93% (+7.5%)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$9.73M |
| 2 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$7.17M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
+$5.85M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$5.47M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.1M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$243K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$121K |
| 4 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
-$64.1K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$31.2K |
SPRB Hedge Fund Activity: Q1 2023 in Review
44 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q1 2023, worth a combined $74.5M — up 273% from $20M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new SPRB positions and 2 closed out — a net gain of 17 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $9.73M. The largest seller was Logos Global Management, exiting entirely with an estimated $1.1M sold.
- 44 institutional investors held Spruce Biosciences (SPRB) as of Q1 2023, up from 28 in Q4 2022.
- Funds reported $74.5M of Spruce Biosciences stock for Q1 2023, up 273% quarter-over-quarter.
- 19 funds opened new Spruce Biosciences positions in Q1 2023 and 2 closed out, a net change of +17 holders.
- The largest Spruce Biosciences buyer in Q1 2023 was Armistice Capital, an estimated $9.73M added.
- The largest Spruce Biosciences seller in Q1 2023 was Logos Global Management, an estimated $1.1M sold.
Based on aggregated 13F filings for Q1 2023.